CASI Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.9900
- Today's High:
- $2.0900
- Open Price:
- $2.0800
- 52W Low:
- $1.84
- 52W High:
- $11.5
- Prev. Close:
- $2.0200
- Volume:
- 14557
Company Statistics
- Market Cap.:
- $0.027 billion
- Book Value:
- 4.92
- Revenue TTM:
- $0.035 billion
- Operating Margin TTM:
- -95.4%
- Gross Profit TTM:
- $0.018 billion
- Gross Profit TTM:
- $0.018 billion
- Profit Margin:
- -92%
- Return on Assets TTM:
- -15.8%
- Return on Equity TTM:
- -30.2%
Company Profile
CASI Pharmaceuticals Inc had its IPO on 1996-06-12 under the ticker symbol CASI.
The company operates in the LIFE SCIENCES sector and (NO DISGNOSTIC SUBSTANCES) industry. CASI Pharmaceuticals Inc has a staff strength of 0 employees.
Stock update
Shares of CASI Pharmaceuticals Inc opened at $2.08 at the start of the last trading session i.e. 2022-11-02.
The stocks traded within a range of $1.99 - $2.09, and closed at $1.99.
This is a -1.49% slip from the previous day's closing price.
A total volume of 14,557 shares were traded at the close of the day’s session.
In the last one week, shares of CASI Pharmaceuticals Inc have slipped by -0.5%.
CASI Pharmaceuticals Inc's Key Ratios
CASI Pharmaceuticals Inc has a market cap of $0.027 billion, indicating a price to book ratio of 0.396 and a price to sales ratio of 0.787.
In the last 12-months CASI Pharmaceuticals Inc’s revenue was $0.035 billion with a gross profit of $0.018 billion and an EBITDA of $-0.032 billion. The EBITDA ratio measures CASI Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, CASI Pharmaceuticals Inc’s operating margin was -95.4% while its return on assets stood at -15.8% with a return of equity of -30.2%.
In Q2, CASI Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 19.7%.
CASI Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- -
- Trailing PE
- -
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-2.257 per share while it has a forward price to earnings multiple of - and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into CASI Pharmaceuticals Inc’s profitability.
CASI Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0.139 and a EV to EBITDA ratio of -0.153. Its price to sales ratio in the trailing 12-months stood at 0.787.
CASI Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $0.000 billion
- Total Liabilities
- $0.000 billion
- Operating Cash Flow
- $0.000 billion
- Capital Expenditure
- $0.000 billion
- Dividend Payout Ratio
- 0%
CASI Pharmaceuticals Inc ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.
CASI Pharmaceuticals Inc ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.
CASI Pharmaceuticals Inc’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.
In 1970, CASI Pharmaceuticals Inc's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.
Comparatively, CASI Pharmaceuticals Inc paid $0 billion in dividends in 1970.
Other key metrics
- Current Trading Price
- $1.99
- 52-Week High
- $11.5
- 52-Week Low
- $1.84
- Analyst Target Price
- $22.67
CASI Pharmaceuticals Inc stock is currently trading at $1.99 per share. It touched a 52-week high of $11.5 and a 52-week low of $11.5. Analysts tracking the stock have a 12-month average target price of $22.67.
Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About CASI Pharmaceuticals Inc
Similar Industry Stocks ((NO DISGNOSTIC SUBSTANCES))
Most Active
Top Gainers
Top Losers
About
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and markets therapeutic and pharmaceutical products in China, the United States, and internationally. The company is headquartered in Rockville, Maryland.